Literature DB >> 11035208

Complete inhibition of purinoceptor agonist-induced nociception by spinorphin, but not by morphine.

H Ueda1, S Matsunaga, M Inoue, Y Yamamoto, T Hazato.   

Abstract

We found that spinorphin, a novel neuropeptide showed analgesia in a different manner compared with morphine. By measuring flexor responses induced by the intraplanter injection of substances, the presence of three different types of sensory neurons were demonstrated. Although spinorphin completely blocked 2-metylthioadenosine (2-MeS ATP, a P2X(3) agonist)-induced responses, morphine did not. On the other hand, morphine-induced blockade of bradykinin (BK, a B(2)-receptor agonist)-responses was attenuated by pertussis toxin (PTX) treatment, whereas that of spinorphin was not. Thus it is suggested that spinorphin has a spectrum of analgesia which covers the blockade of nociception insensitive to morphine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035208     DOI: 10.1016/s0196-9781(00)00262-x

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

1.  Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception.

Authors:  Arpad Dobolyi; Hiroshi Ueda; Hitoshi Uchida; Miklós Palkovits; Ted B Usdin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

2.  Endogenous opioid mechanisms partially mediate P2X3/P2X2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain.

Authors:  Steve McGaraughty; Prisca Honore; Carol T Wismer; Joseph Mikusa; Chang Z Zhu; Heath A McDonald; Bruce Bianchi; Connie R Faltynek; Michael F Jarvis
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

3.  Algogen-specific pain processing in mouse spinal cord: differential involvement of voltage-dependent Ca(2+) channels in synaptic transmission.

Authors:  Akemi Kato; Tsuyako Ohkubo; Kenji Kitamura
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Entropy-driven binding of opioid peptides induces a large domain motion in human dipeptidyl peptidase III.

Authors:  Gustavo A Bezerra; Elena Dobrovetsky; Roland Viertlmayr; Aiping Dong; Alexandra Binter; Marija Abramic; Peter Macheroux; Sirano Dhe-Paganon; Karl Gruber
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

5.  Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration.

Authors:  Steve McGaraughty; Carol T Wismer; Chang Z Zhu; Joseph Mikusa; Prisca Honore; Katharine L Chu; Chih-Hung Lee; Connie R Faltynek; Michael F Jarvis
Journal:  Br J Pharmacol       Date:  2003-11-17       Impact factor: 8.739

6.  Non-peptidergic small diameter primary afferents expressing VGluT2 project to lamina I of mouse spinal dorsal horn.

Authors:  Jennifer N Clarke; Rebecca L Anderson; Rainer V Haberberger; Ian L Gibbins
Journal:  Mol Pain       Date:  2011-12-08       Impact factor: 3.395

7.  The Development of Translational Biomarkers as a Tool for Improving the Understanding, Diagnosis and Treatment of Chronic Neuropathic Pain.

Authors:  David A Buckley; Elaine M Jennings; Nikita N Burke; Michelle Roche; Veronica McInerney; Jonathan D Wren; David P Finn; Patrick C McHugh
Journal:  Mol Neurobiol       Date:  2017-03-30       Impact factor: 5.590

Review 8.  Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination.

Authors:  Hiroshi Ueda
Journal:  Mol Pain       Date:  2008-04-01       Impact factor: 3.395

9.  Food-Derived Hemorphins Cross Intestinal and Blood-Brain Barriers In Vitro.

Authors:  Dorothée Domenger; Benoit Cudennec; Mostafa Kouach; Véronique Touche; Christophe Landry; Jean Lesage; Fabien Gosselet; Sophie Lestavel; Jean-François Goossens; Pascal Dhulster; Rozenn Ravallec
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-10       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.